Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.78 |
| ▸ | CA2 | P00918 | 4/20 | 0.71 |
| ▸ | CA1 | P00915 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2332212 | 0.93 | MAP2K1 (0.81) | MAP2K1CA2CA1 | |
| SCHEMBL2452613 | 0.91 | MAP2K1 (0.77) | MAP2K1CA2CA1 | |
| SCHEMBL2331678 | 0.89 | MAP2K1 (0.79) | MAP2K1CA2CA1 | |
| SCHEMBL2327977 | 0.89 | MAP2K1 (0.79) | MAP2K1CA2CA1 | |
| SCHEMBL2328376 | 0.88 | MAP2K1 (0.78) | MAP2K1CA2CA1 | |
| SCHEMBL1111356 | 0.88 | MAP2K1 (1.00) | MAP2K1CA2CA1 | |
| SCHEMBL2327995 | 0.87 | MAP2K1 (0.82) | MAP2K1CA2CA1 | |
| SCHEMBL2331133 | 0.87 | MAP2K1 (0.77) | MAP2K1CA2CA1 | |
| SCHEMBL2359818 | 0.87 | MAP2K1 (0.82) | MAP2K1CA2CA1 | |
| SCHEMBL2327691 | 0.87 | MAP2K1 (0.82) | MAP2K1CA2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110237592-A1 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | claimed |
| EP-2356091-A2 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | Bayer Schering Pharma AG (DE) | 2011-08-17 | — | — | EP | claimed |
| WO-2010051935-A2 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-05-14 | — | — | WO | claimed |
| US-20110237592-A1 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237592-A1 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237592-A1 | SUBSTITUTED AMIDO PHENOXYBENZAMIDES | EDNRB, CCNB3, FLT1 | MAP2K1 3337/4885CA2 2161/4885CA1 4766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.